Study to Evaluate D-1553 in Subjects With Solid Tumors
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is a phase 1/2, open label study of D-1553 single agent and combination treatment to
assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and
antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C
mutation.